- Home
- LOCO vs ALDX Comparison
LOCO vs ALDX Comparison
Compare LOCO & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOCO | ALDX |
|---|---|---|
| Founded | 1980 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.6M | 293.0M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LOCO | ALDX |
|---|---|---|
| Price | $10.73 | $5.18 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $15.75 | $9.50 |
| AVG Volume (30 Days) | 236.4K | ★ 1.6M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 0.89 | N/A |
| Revenue | ★ $480,815,000.00 | N/A |
| Revenue This Year | $5.67 | N/A |
| Revenue Next Year | $1.42 | $36.25 |
| P/E Ratio | $12.02 | ★ N/A |
| Revenue Growth | ★ 2.09 | N/A |
| 52 Week Low | $8.29 | $1.14 |
| 52 Week High | $12.65 | $7.20 |
Technical Indicators
Market Signals| Indicator | LOCO | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 51.45 |
| Support Level | $10.46 | $4.98 |
| Resistance Level | $10.89 | $5.75 |
| Average True Range (ATR) | 0.27 | 0.46 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 19.53 | 66.76 |
Price Performance
Historical ComparisonAbout LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. Restaurant locations are typically free-standing and include drive-thrus, and menus include many low-priced options. Poultry is the company's largest food cost, accounting for roughly 38% of total food and paper cost, and the company manages that commodity price risk by using multiple suppliers and entering supply contracts of varying lengths depending on market conditions.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.